Interferon Gamma-Dependent Intestinal Pathology Contributes to the Lethality in Bacterial Superantigen-Induced Toxic Shock Syndrome by Tilahun, Ashenafi Y. et al.
Interferon Gamma-Dependent Intestinal Pathology
Contributes to the Lethality in Bacterial Superantigen-
Induced Toxic Shock Syndrome
Ashenafi Y. Tilahun
1, Marah Holz
1, Tsung-Teh Wu
2, Chella S. David
1, Govindarajan Rajagopalan
1*
1Department of Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America, 2Department of Anatomic Pathology, Mayo Clinic
College of Medicine, Rochester, Minnesota, United States of America
Abstract
Toxic shock syndrome (TSS) caused by the superantigen exotoxins of Staphylococcus aureus and Streptococcus pyogenes is
characterized by robust T cell activation, profound elevation in systemic levels of multiple cytokines, including interferon-c
(IFN-c), followed by multiple organ dysfunction and often death. As IFN-c possesses pro- as well as anti-inflammatory
properties, we delineated its role in the pathogenesis of TSS. Antibody-mediated in vivo neutralization of IFN-c or targeted
disruption of IFN-c gene conferred significant protection from lethal TSS in HLA-DR3 transgenic mice. Following systemic
high dose SEB challenge, whereas the HLA-DR3.IFN-c
+/+ mice became sick and succumbed to TSS, HLA-DR3.IFN-c
2/2 mice
appeared healthy and were significantly protected from SEB-induced lethality. SEB-induced systemic cytokine storm was
significantly blunted in HLA-DR3.IFN-c
2/2 transgenic mice. Serum concentrations of several cytokines (IL-4, IL-10, IL-12p40
and IL-17) and chemokines (KC, rantes, eotaxin and MCP-1) were significantly lower in HLA-DR3.IFN-c
2/2 transgenic mice.
However, SEB-induced T cell expansion in the spleens was unaffected and expansion of SEB-reactive TCR Vb8
+ CD4
+ and
CD8
+ T cells was even more pronounced in HLA-DR3.IFN-c
2/2 transgenic mice when compared to HLA-DR3.IFN-c
+/+ mice. A
systematic histopathological examination of several vital organs revealed that both HLA-DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2
transgenic mice displayed comparable severe inflammatory changes in lungs, and liver during TSS. Remarkably, whereas the
smallintestines from HLA-DR3.IFN-c
+/+transgenicmicedisplayedsignificant pathologicalchangesduringTSS,thearchitecture
of small intestines in HLA-DR3.IFN-c
2/2 transgenic mice was preserved. In concordance with these histopathological changes,
the gut permeability to macromolecules was dramatically increased in HLA-DR3.IFN-c
+/+ but not HLA-DR3.IFN-c
2/2 mice
during TSS. Overall, IFN-c seemed to play a lethal role in the immunopathogenesis of TSS by inflicting fatal small bowel
pathology. Our study thus identifies the important role for IFN-c in TSS.
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Introduction
Toxic shock syndrome (TSS) is a serious systemic illness caused
by the Gram-positive cocci, Staphylococcus aureus or Streptococcus
pyogenes [1,2]. However, other organisms could be responsible for
TSS as well [3]. Toxic shock syndrome caused by S. aureus and S.
pyogenes could be either menstrual or non-menstrual, has a rapid
onset and can result in mortality, if not treated promptly [4,5,6].
While S. aureus and S. pyogenes elaborate several exotoxins, the
superantigen (SAg) exotoxins are directly implicated in the
etiopathogenesis of TSS [7]. Mechanistically, the SAg produced
by these bacteria bind directly to a or b chain of the MHC class II
molecules, without undergoing any intracellular processing.
Subsequently, the MHC class II-bound SAg robustly activate
both CD4
+ and CD8
+ T cells by interacting directly with certain T
cell receptor variable region b (TCR Vb) chain families,
irrespective of the antigen specificities of the T cells [8]. The T
cells activated by SAg rapidly produce large amounts of cytokines
and chemokines resulting in a sudden surge in the systemic levels
of these biological mediators. This process, called systemic
inflammatory response syndrome (SIRS), may lead to multiple
organ dysfunction syndrome or MODS, wherein several vital
organs within the body fail to perform their physiological
functions. When MODS is not managed promptly, this will
progress to irreversible end-stage organ failure and culminates in
mortality. Apart from TSS, SAg also play an important role in the
etiopathogenesis of several other acute systemic diseases caused by
S. aureus and S. pyogenes, including sepsis [9,10,11]. In addition,
certain superantigens, such as staphylococcal enterotoxin B (SEB),
could be used as biological weapons [12]. Exposure to weaponized
SEB can also causes a syndrome identical to TSS and can cause
mortality.
The immunopathogenesis of TSS and related acute syndromes
caused by SAg is poorly understood [13]. Currently, there are no
specific therapies available to treat these clinical conditions and
they are managed only by supportive therapy. Given that TSS is
characterized by a robust elevation in systemic levels of several
cytokines and chemokines, neutralization of key cytokines and/or
chemokines could have therapeutic potential, as in other
inflammatory diseases [14,15]. In this context, while neutralization
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16764Figure 1. In vivo antibody mediated neutralization of IFN-c protects from lethal SEB-induced TSS. Age-matched HLA-DR3 transgenic
mice were challenged with SEB (50 mg) immediately followed by indicated amounts of monoclonal rat anti-mouse IFN-c or isotype control. Mice were
closely monitored for symptoms of TSS.
doi:10.1371/journal.pone.0016764.g001
Figure 2. Effect of antibody mediated neutralization of IFN-c on SEB-induced cytokine and chemokine responses in vivo. Age-
matched HLA-DR3 transgenic mice were challenged with SEB (5 mg) immediately followed by 100 mg of goat anti-mouse IFN-c or control goat
antibodies. Mice were bled 3 hrs later and serum cytokine levels were determined using a multiplex suspension array system (Bio-Plex, Bio-Rad). Each
bar represents the mean6SE of 4–6 mice.
doi:10.1371/journal.pone.0016764.g002
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TSS [16], clinical studies have shown that antagonizing the
biological functions of TNF-a is ineffective during sepsis/TSS in
human patients and might even be counter productive [17].
Therefore, other molecular targets need to be identified for
treatment and/or prevention of TSS.
We and others have consistently observed that the expression of
IFN-c gene as well as systemic levels of IFN-c are dramatically
elevated during TSS [18,19,20,21,22,23,24], suggesting that IFN-
c could play an important role in the pathogenesis of TSS.
However, the contradictory roles of IFN-c in various inflamma-
tory diseases have raised several unanswered questions regarding
the pathogenic role for IFN-c in TSS. IFN-c has been traditionally
considered as a pro-inflammatory cytokine responsible for eliciting
immunopathology in several models of inflammation [25].
However, with the discovery of IL-17, and availability of newer
reagents, a different role for IFN-c has emerged in recent years.
Unlike the previously held notions, IFN-c has now been shown to
protect from immunopathology in different models of inflamma-
tion (reviewed in Ref. [26]). For example, in the mouse model of
multiple sclerosis, in vivo neutralization of IFN-c resulted in
exaggerated immune response and central nervous system
immunopathology [27]. Similarly, in a mouse model of inflam-
matory bowel disease, IFN-c has been shown to have anti-
inflammatory role by suppressing IL-23 [28]. Collagen-induced
arthritis is also exaggerated in the absence of IFN-c signaling [29].
However, in the murine endotoxic shock model, IFN-c seems to
play a pathogenic role [30]. Similarly, IFN-c has been shown to be
lethal in lipopolysaccharide-sensitization models of TSS [31].
However, the role of IFN-c in TSS without any additional
sensitization protocols has not been thoroughly investigated using
animal models that recapitulate human TSS. Also, the mecha-
nisms by which IFN-c either predisposes or protects from TSS
have not been shown. Once the role of IFN-c in the
immunopathogenesis of TSS is clarified, novel clinical protocols
could be developed either to treat or prevent TSS. With this
background, we explored the role of IFN-c in the immunopatho-
genesis of TSS using HLA-DR3 transgenic mice. Our study
identifies a novel role for IFN-c in the pathogenesis of TSS.
Materials and Methods
Mice
AEu.HLA-DR3 transgenic mice expressing the functional HLA-
DRA1*0101 and HLA-DRB1*0301 transgenes on the complete
mouse MHC class II-deficient background have been described
earlier and were used in this study [18]. HLA-DR3 transgenic
mice are extremely sensitive to TSS without the use of any
sensitizing agents and faithfully recapitulate human TSS [19].
AEu.HLA-DR3.IFN-c
2/2 mice were generated by mating
AEu.HLA-DR3 transgenic mice with C57BL6.IFN-c
2/2 mice
(Jackson Laboratory, Bar Harbor, ME) as per standard breeding
protocols. Mice expressing HLA-DR3 transgene and lacking
endogenous MHC class II as well as IFN-c were identified by
PCR, selectively bred to generate the AEu.HLA-DR3.IFN-c
2/2
line. Mice were bred within the barrier facility of Mayo Clinic
Immunogenetics Mouse Colony (Rochester, MN) and moved to a
conventional facility after weaning. All the experiments were
approved by the Mayo Clinic Institutional Animal Care and Use
Committee (IACUC). The AAALAC Accreditation Number is
Figure 3. Effect of antibody mediated neutralization of IFN-c on SEB-induced splenic T cell expansion and thymocyte deletion. Age-
matched HLA-DR3 transgenic mice were challenged with SEB (5 mg) immediately followed by 100 mg of goat anti-mouse IFN-c or control goat
antibodies. Mice were killed 3 days later and distribution of different T cell subsets in the spleen (A and B) and thymus (C and D) was determined by
flow cytometry. Each bar represents the mean6SE of 4–6 mice.
doi:10.1371/journal.pone.0016764.g003
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was covered under the protocols A29507 and A26408.
Reagents
Endotoxin-reduced, highly purified staphylococcal enterotoxin
B (SEB, Toxin Laboratories, Sarasota, FL) was dissolved in
phosphate-buffered saline (PBS) at 1 mg/ml and stored frozen at -
80uC in aliquots. Affinity purified goat anti murine-IFN-c
neutralizing antibodies (AF-485-NA) and goat IgG isotype control
were purchased from R&D systems (Minneapolis, MN). The
monoclonal rat anti-mouse IFN-c antibody (clone HB-170) was
purified from culture supernatants of hybridoma cell line grown in
roller bottles as per standard procedure at Mayo antibody core
facility (Mayo Clinic, Rochester, MN).
SEB injections and response
For serum cytokine analyses, HLA-DR3.IFN-c
+/+ and HLA-
DR3.IFN-c
2/2 transgenic mice were challenged with 10 mgo f
SEB in 200 ml PBS by intra-peritoneal route, bled at 3 hours. For
in vivo IFN-c neutralization, mice were first challenged 5 mgo f
SEB in 200 ml PBS. Immediately following this, mice received
100 mg of affinity purified goat anti-mouse IFN-c neutralizing
antibody (AF-485-NA) or 100 mg of goat IgG isotype control, all
injected intra-peritoneally. Mice were bled at 3 hours for serum
cytokine analysis using a multiplex bead assay, per the
manufacturer’s protocol using their software and hardware
(Bio-Plex, Bio-Rad). For experiments involving flow cytometric
analyses, mice were killed on specified days after SEB challenge
and distribution of CD4
+ and CD8
+ T cells expressing TCR Vb6
or TCR Vb8 was determined in indicated tissues by flow
cytometry using flurochrome conjugated antibodies (BD biosci-
ences (San Jose, CA).
Induction of toxic shock with SEB
Mice received either 50 or 100 mg of SEB in 200 ml PBS
through intra-peritoneal route. Mice were closely monitored for
the symptoms of shock. Rectal temperature was recorded at 0, 3,
6, 24, 48 and 72 hours. General physical activity of mice was
scored on an arbitrary scale of 1–4, with 4 being normal activity
and 1 being moribund (euthanized subsequently). For in vivo
protection studies, mice were challenged with SEB (50 mg/mouse),
immediately followed by indicated amounts of anti-IFN-c
monoclonal antibodies given by intra-peritoneal injection. Mice
were closely monitored as above. Administration of D-galactos-
amine (D-galN) sensitizes mice to TSS and causes rapid death in a
TNF-a-dependent manner [13,16]. Therefore, we also investigat-
ed whether there is a differential susceptibility of HLA-DR3.IFN-
c
+/+ and HLA-DR3.IFN-c
2/2 transgenic mice to D-galN-
sensitized TSS. For this, mice were first injected with 5 mgo f
SEB in 200 ml PBS by intra-peritoneal injection, immediately
followed by 30 mg of D-galN also injected through intra-
peritoneal route.
Gut permeability
Changes in intestinal permeability were determined using
4 KDa FITC-labeled dextran [32]. HLA-DR3.IFN-c
+/+ and
HLA-DR3.IFN-c
2/2 mice were challenged with SEB (50 mg/
mouse) as above. 24, 48 and 72 hours after SEB challenge, mice
were deprived of food for 3 hours. Naı ¨ve mice were also deprived
of food for 3 hours. All mice were then gavaged with FITC–
labeled dextran (0.6 mg/G body weight). Subsequently, all mice
were sacrificed 3 hours after gavage and blood was collected by
cardiac puncture. Sera were separated by centrifugation and
stored frozen at 270uC until time for analysis. Serum content of
FITC-dextran was determined using a microplate reader to
measure fluorescence (excitation, 490 nm; emission, 525 nm).
Statistics
The statistical significance of the survival curves were
determined by ‘‘Log-rank (Mantel-Cox) Test’’ using the
software GraphPad Prism (version 3.0a; San Diego, CA). Other
results were compared applying Student’s t test using the same
software.
Figure 4. Effect of IFN-c deficiency on SEB-induced TSS. Age-
matched HLA-DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2 transgenic mice were
challenged with SEB (50 mg) and monitored closely. Data from 6–13
mice in each group.
doi:10.1371/journal.pone.0016764.g004
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In vivo antibody-mediated neutralization of IFN-c
protects from SEB-induced TSS
As shown in Fig. 1, HLA-DR3 transgenic mice challenged with
SEB alone invariably succumbed to SEB-induced TSS as we have
previously demonstrated. Similarly, HLA-DR3 transgenic mice
challenged with SEB and treated with rat IgG isotype control
antibodies also succumbed to TSS. On the contrary, only one out
of six HLA-DR3 transgenic mice challenged with SEB and treated
with anti-IFN-c (400 mg/mouse) succumbed to TSS. Anti-IFN-c
mAb conferred similar protection from TSS even when the dose of
antibody was reduced to 200 mg/mouse. This experiment clearly
suggested that IFN-c plays a lethal role in the immunopathogen-
esis of SAg-induced TSS and that antibody-mediated neutraliza-
tion of IFN-c could protect from TSS.
Effect of antibody mediated neutralization of IFN-c on
SEB-induced cytokine and chemokine response in vivo
As illustrated in Fig. 2, naı ¨ve HLA-DR3.IFN-c
+/+ mice had
very low or undetectable levels of several cytokines/chemokines
tested. Within 3 hours following SEB challenge, these cytokines/
chemokines showed a significant elevation. Administration of
neutralizing antibodies to IFN-c immediately following SEB
challenge caused changes in the concentrations of certain
cytokines/chemokines in the serum. First of all, serum levels of
IFN-c were significantly reduced (p,0.05) when compared to
SEB-challenged mice treated with isotype control. In addition,
chemokines such as rantes (CCL5) and KC (CXCL1) were also
significantly reduced. While SEB challenged mice treated with
control IgG had nearly 450 to 500 pg/ml of IL-17 in their sera,
anti-IFN-c treated mice had a 2.2-fold reduction in the serum IL-
Figure 5. Effect of IFN-c deficiency on SEB-induced cytokine responses in vivo. Age-matched HLA-DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2
transgenic mice were challenged with SEB (10 mg). Mice were bled at 3 hrs and serum cytokine levels were determined using a multiplex suspension
array system (Bio-Plex, Bio-Rad).
doi:10.1371/journal.pone.0016764.g005
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markedly reduced in anti-IFN-c treated mice when compared to
isotype treated control mice, but this reduction was not
statistically significant. Notably, anti-IFN-c treated mice had
nearly a 2-fold increase in serum IL-5 levels when compared to
control IgG treated mice. Thus, in vivo neutralization of IFN-c
modulated the systemic levels of other cytokines/chemokines as
well.
Effect of antibody mediated neutralization of IFN-c on
SEB-induced splenic T cell expansion and thymocyte
deletion
It is well established that following a single SEB challenge in
vivo, both CD4
+ and CD8
+ mature T cells expressing TCR Vb8
(SEB-reactive) but not Vb6 (SEB non-reactive), expand in the
spleens and lymph nodes by day 3. Therefore, we next investigated
whether in vivo neutralization of IFN-c had any effect on T cell
expansion. As shown in Fig. 3A and B, when compared to naı ¨ve
HLA-DR3 mice, mice that were challenged with SEB, as would be
expected, had significantly increased numbers of both CD4
+ and
CD8
+ mature T cells expressing TCR Vb8 but not Vb6. Spleens
from mice challenged with SEB and treated anti-IFN-c antibodies
harbored more total CD4
+ and CD8
+ as well as respective TCR
Vb8
+ T cells when compared to mice challenged with SEB alone
or mice challenged with SEB and treated with isotype control
antibodies. However, the differences were not statistically
significant (Fig. 3B). Unlike the mature peripheral T cells, the
immature CD4CD8 double positive thymocytes undergo massive
deletion following a single injection of SEB by day 3 [33]. Thus,
thymocyte deletion is also considered a hallmark of superantigen-
mediated immune activation in vivo. As can be seen from Fig. 3C
and D, while neutralization of IFN-c appeared to confer some
protection of CD4CD8 double positive T cells from apoptosis, this
was not statistically significant. Overall, in vivo neutralization of
IFN-c had little inhibitory effect on SEB-induced expansion of
mature T cells. This suggested that the protective effect of IFN-c
neutralization is not through inhibition of T cell activation or
expansion.
Targeted disruption of IFN-c protects from SEB-induced
TSS
We next wished to delineate the mechanisms by which IFN-c
contributed to the pathogenesis of TSS. Due to several advantages,
we used HLA-DR3 transgenic mice with targeted disruption of
IFN-c gene for these studies. First of all, we confirmed the
detrimental role for IFN-c in SEB-induced TSS. HLA-DR3.IFN-
c
+/+ and HLA-DR3.IFN-c
2/2 mice were challenged with 50 mg
of SEB and monitored closely. As shown in Fig. 4, HLA-
DR3.IFN-c
+/+ mice challenged with SEB became hypothermic,
lethargic and 11 of the 13 mice died of TSS by 72 hours. On the
other hand, the HLA-DR3.IFN-c
2/2 mice remained healthy,
maintained their body temperature and maintained normal
physical activity (p,0.05, Fig. 4A and B). Moreover, only 1 out
of the 10 HLA-DR3.IFN-c
2/2 mice died of TSS (p=0.0007,
Fig. 4C). HLA-DR3.IFN-c
2/2 resisted lethal SEB-induced TSS
even when the dose of SEB was doubled to 100 mg/mouse. While
the HLA-DR3.IFN-c
+/+ became progressively sick, the HLA-
DR3.IFN-c
2/2 mice remained healthy throughout the study (Fig.
S1). While 4 out of 4 HLA-DR3.IFN-c
+/+ transgenic mice died
within the 3-day follow-up, only 1 out of 6 HLA-DR3.IFN-c
2/2
Figure 6. Effect of IFN-c deficiency on SEB-induced chemokine responses in vivo. Age-matched HLA-DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2
transgenic mice were challenged with SEB (10 mg). Mice were bled at 3 hrs and serum chemokine levels were determined using a multiplex
suspension array system (Bio-Plex, Bio-Rad).
doi:10.1371/journal.pone.0016764.g006
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that IFN-c plays a detrimental role in the in the pathogenesis of
TSS.
Interferon-c deficiency modulates SEB-induced acute
cytokine/chemokine production in vivo
First of all, naı ¨ve HLA-DR3.IFN-c
+/+ mice had very low or
undetectable levels of several cytokines/chemokines tested.
Similarly, naı ¨ve HLA-DR3.IFN-c
2/2 mice also had undetectable
levels of serum cytokines (Fig. 5) and chemokines (Fig. 6).
Nonetheless, serum level of IL-5 was significantly higher in
naı ¨ve HLA-DR3.IFN-c
2/2 when compared to their naı ¨ve
HLA-DR3.IFN-c
+/+ counterpart (104.864.950 versus 58.006
10.49 pg/ml, respectively, P,0.05), while level of IL-12p40 was
significantly lower in naı ¨ve HLA-DR3.IFN-c
2/2 when compared
to their naı ¨ve HLA-DR3.IFN-c
+/+ counterpart (142.9628.58
versus 310.2628.39 pg/ml, respectively, P,0.05). We next
explored if challenging with SEB brings about differential cytokine
response in HLA-DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2 trans-
genic mice.
Following SEB challenge, the serum levels of all the cytokines/
chemokines were dramatically elevated in SEB-treated HLA-
DR3.IFN-c
+/+ HLA-DR3 mice. Even in HLA-DR3.IFN-c
2/2
mice, serum levels of several cytokines/chemokines were elevated
following SEB challenge. However, the fold inductions were
different. Concentrations of certain cytokines were not significantly
different between HLA-DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2
mice, e.g., IL-1a, IL-1b, IL-3, IL-6, IL-9, G-CSF, TNF-a, MIP-1a
and MIP-1b, (Fig. 5 and 6). Some cytokines/chemokines were
significantly lower in SEB challenged HLA-DR3.IFN-c
2/2
mice. These included, IL-2 (p,0.04), IL-4 (p,0.002), IL-
12p40 (p,0.05), IL-17 (p,0.005), KC (p,0.03) and Rantes
(p,0.007). Some cytokines were higher in HLA-DR3.IFN-c
2/2,
e.g., IL-5. The mean serum IL-5 concentration in SEB
challenged HLA-DR3.IFN-c
2/2 mice was 2-fold higher when
compared to HLA-DR3.IFN-c
+/+ mice but not significant
(p=0.07). As expected, serum IFN-c concentration was
undetectable (background level of the assay) in SEB challenged
HLA-DR3.IFN-c
2/2 mice whereas it ranged from 700 to
4000 pg/ml (mean 18306387 pg/ml) in SEB challenged HLA-
DR3.IFN-c
+/+ mice. These results confirmed the known effects
of IFN-c that it can regulate the production of several cytokines
and chemokines. More importantly, it should be noted that
antibody mediated neutralization of IFN-c also resulted in
similar modulation in systemic cytokine/chemokines levels
(Fig. 2). However, IFN-c
2/2 mice obviously expressed more
profound changes as would be expected. It should be noted that
TNF-a has been implicated as a key molecular player in the
Figure 7. Effect of IFN-c deficiency on SEB-induced splenic T cell expansion and thymocyte deletion. Age-matched HLA-DR3.IFN-c
+/+
and HLA-DR3.IFN-c
2/2 transgenic mice were challenged with SEB (10 mg). Mice were killed 3 days later and distribution of different T cell subsets in
the spleen (A and B) and thymus (C and D) was determined by flow cytometry. Each bar represents the mean6SE of 4–6 mice.
doi:10.1371/journal.pone.0016764.g007
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serum TNF-a levels between the TSS-susceptible HLA-
DR3.IFN-c
+/+ and TSS-resistant HLA-DR3.IFN-c
2/2 mice.
Interferon-c deficient DR3 transgenic mice are
susceptible to SEB-induced TSS with D-gal sensitization
SAg fail to bind to murine MHC class II molecules more
effectively and hence mice are resistant to TSS. Therefore,
conventional mice are artificially made susceptible to TSS by using
sensitizing agents such as D-galN [13,34]. It has been shown that
TNF-a plays a very important role in the pathogenesis of D-galN
sensitized TSS [16,35]. Since HLA-DR3.IFN-c
2/2 transgenic
mice still had elevated levels of TNF-a, we next studied whether
these mice will be susceptible to TSS with D-galN sensitization.
Interestingly, both HLA-DR3.IFN-c
+/+ (Mortality - 6/6) and
HLA-DR3.IFN-c
2/2 (Mortality - 4/4) transgenic mice were
equally susceptible to TSS with D-galN sensitization. Both HLA-
DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2 transgenic mice rapidly
became hypothermic and failed to survive beyond 9 hours post-
SEB challenge. The observations that HLA-DR3.IFN-c
2/2
transgenic mice are resistant to lethal TSS without D-galN
sensitization which mimics human TSS, but are still susceptible
TSS with D-galN sensitization underscored significant differences
in the immunopathogenesis between the two models of TSS.
Protection from SEB-induced TSS in HLA-DR3.IFN-c
2/2
transgenic mice is not due to defective T lymphocyte
response to SEB.
IFN-c deficiency did not limit the SEB-induced expansion of
splenic TCR Vb8
+ T cells (Fig. 7A). Rather, there was a more
robust expansion of TCR Vb8
+ but not Vb6
+ CD4 and CD8 T
cells at day 3 in HLA-DR3.IFN-c
2/2 mice (Fig. 7A). When the
percentages were converted to absolute numbers, the differences
were more appreciable (Fig. 7B). With respect to the thymocytes
(Fig. 7C and D), administration of SEB resulted in deletion of
immature CD4CD8 double positive thymocytes equally in HLA-
DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2 transgenic mice. This
indicated that protection from SEB-induced TSS is not due to
defective T cell response to SEB in HLA-DR3.IFN-c
2/2 mice.
On the other hand, IFN-c appeared to dampen SEB-induced T
cell expansion. In vitro stimulation of splenocytes from HLA-
DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2 mice showed similar
responses in that HLA-DR3.IFN-c
2/2 splenocytes proliferated
more vigorously to SEB (Fig. S2). Increased T cell proliferation in
vitro or increased expansion of T cells in vivo in HLA-DR3.IFN-
c
2/2 mice was probably not due to increased expression of HLA-
DR3 molecules in HLA-DR3.IFN-c
2/2 mice because of compa-
rable numbers of CD4
+ T cells were present in both groups of
mice in both thymus and spleen (Fig. 7). Similarly, the TCR Vb8
+
T cells were also not significantly different between naı ¨ve HLA-
DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2 transgenic mice (Fig. 7A
and B).
In the next set of experiments, we studied if there are any
defects in the kinetics of T cell activation in HLA-DR3.IFN-c
2/2
mice. For this, we collected splenocytes at 24, 48 and 72 hrs after
SEB challenge from both HLA-DR3.IFN-c
+/+ and HLA-
DR3.IFN-c
2/2 mice and studied the expression profile of
activation markers such as CD69 and CD62L. Consistent with
the above data, there appeared to be no defect in the kinetics of T
cell activation in HLA-DR3.IFN-c
2/2 mice (Fig. S3). Overall,
protection from TSS in HLA-DR3.IFN-c
2/2 mice was not due to
defects in T cell activation.
Figure 8. Effect of IFN-c deficiency on SEB-induced pulmonary immunopathology. Age-matched HLA-DR3.IFN-c
+/+ (A and C) and HLA-
DR3.IFN-c
2/2 (B and D) transgenic mice were left untreated (A and B) or challenged with SEB (50 mg, C and D). Mice were killed 48 hrs later, lungs
were collected in buffered formalin and processed for H&E. The bar corresponds to 100 mM.
doi:10.1371/journal.pone.0016764.g008
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Toxic shock syndrome is characterized by multiple organ
dysfunction. We have shown previously that HLA-DR3 transgenic
mice challenged with SEB show significant multi-organ inflam-
mation (involving lungs, liver, kidneys, heart and the intestines)
analogous to human TSS. Since HLA-DR3.IFN-c
2/2 mice were
protected from lethality associated with TSS, we next compared
the extent of inflammatory changes in several organs between the
HLA-DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2 transgenic mice to
gain some insights into the mechanisms by which IFN-c plays a
lethal role in TSS. As we have previously demonstrated, lungs
(Fig. 8) and liver (Fig. 9) from HLA-DR3.IFN-c
+/+ mice
challenged with SEB showed significant inflammatory changes.
Surprisingly, these organs from HLA-DR3.IFN-c
2/2 mice
challenged with SEB also showed significant inflammatory
changes. These findings suggested that protection from SEB-
induced lethality TSS in HLA-DR3.IFN-c
2/2 mice is not due to
attenuated pathology in lungs and liver.
Minimal intestinal pathology and conserved intestinal
permeability in interferon-c deficient mice during TSS
One of the characteristic findings in SEB-induced TSS is
extensive pathology to the small intestines, which is associated with
changes in the gut permeability to macromolecules. Therefore, we
next investigated whether reduced gut pathology could explain
protection of HLA-DR3.IFN-c
2/2 transgenic mice from TSS. As
previously demonstrated by us, HLA-DR3.IFN-c
+/+ transgenic
mice challenged with SEB had significant pathological changes in
the small intestine. There was dramatic shortening of villi in the
small intestine. The integrity of the intestinal epithelial layer was
completely altered. There was also complete loss of architecture of
Figure 9. Effect of IFN-c deficiency on SEB-induced hepatic immunopathology. Age-matched HLA-DR3.IFN-c
+/+ (A to D) and HLA-DR3.IFN-
c
2/2 (E and H) transgenic mice were challenged with PBS (A, B and E, F) or challenged with SEB (50 mg) (C, D and G, H). Mice were killed 48 hrs later,
livers were collected in buffered formalin and processed for H&E. The bar corresponds to 100 mM.
doi:10.1371/journal.pone.0016764.g009
Gamma Interferon in Toxic Shock Syndrome
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e16764the lamina propria and submucosa throughout the small intestine.
We could also detect the presence of large numbers of apoptotic
cells in the intestinal epithelial layer. Large amounts of epithelial
cell debris could be readily appreciated in the lumen of the small
intestines from HLA-DR3.IFN-c
+/+ mice with TSS (Fig. 10, 11
and Figures S4 and S5). On the other hand, intestinal segments
from HLA-DR3.IFN-c
2/2 mice challenged with SEB showed
highly preserved histological architecture. There were minimal
damages to the epithelial layer and the heights of the villi were
preserved. Since the expression profiles of activation markers and
expansion of T cells expressing TCR Vb8 in HLA-DR3.IFN-c
2/2
was comparable to that seen in HLA-DR3.IFN-c
+/+ mice (Fig. S2),
this rules out the possibility that subdued gut pathology in HLA-
DR3.IFN-c
2/2 mice is due to defective T cell activation.
In concordance with the histological changes in the gut, there
was a significant change in gut permeability to macromolecules
such as FITC-dextran in HLA-DR3.IFN-c
+/+ mice (Fig. 12).
However, as expected, SEB challenged HLA-DR3.IFN-c
2/2
transgenic mice showed minimal changes in gut permeability as
evidenced by lack of increase in fluorescence activity in sera at
different time points. On the contrary, the fluorescence activity in
the sera from HLA-DR3.IFN-c
+/+ transgenic mice significantly
increased at 24 and 48 hours correlating with the gut pathology.
However, at 72 hours, the fluorescent activity was reduced to
baseline levels. This correlated with the loss of body weights in
HLA-DR3.IFN-c
+/+ transgenic mice (Fig. 4). Combined with the
histopathological picture, altered gut permeability and the
significant drop in body weight in HLA-DR3.IFN-c
+/+ transgenic
mice with time, it could be interpreted that there is a permanent
damage to the gut epithelium as a result of which the absorptive
functions of the epithelium is completely lost. Since HLA-
DR3.IFN-c
2/2 mice did not show any significant pathological
changes in the gut, maintained their body weights and preserved
their gut permeability to macromolecules, we could conclude that
IFN-c-dependent gut pathology contributed to the lethality in
TSS.
Discussion
Toxic shock syndrome and other acute serious diseases that are
particularly caused by S. aureus and S. pyogenes are attributed to the
unique ability of their superantigen exotoxins to cause massive T
cell activation and induce cytokine/chemokine secretion [36].
However, the exact molecular pathways by which these events
lead to multiple organ dysfunction and ultimately death are not
clearly understood [2]. As a result, there are no specific therapies
available as of today to treat TSS. Since TSS is characterized by a
systemic cytokine/chemokine storm, antagonizing or neutralizing
the functions of selected pathogenic cytokines and/or chemokines
could be beneficial. Given that numerous cytokines and chemo-
kines are elevated during TSS, identifying a precise target with
therapeutic utility could be a daunting task. Lack of appropriate
animal models that closely recapitulate the human disease further
complicates the problem.
It is well known that SAg bind more effectively with human
MHC class II molecules than to mouse MHC class II molecules.
Therefore, we have established that unlike the conventional mice
strains, mice that transgenically express the HLA-DR or HLA-DQ
molecules in the absence of any endogenous MHC class II
molecules, mount a robust immune response to bacterial
Figure 10. Effect of IFN-c deficiency on SEB-induced intestinal immunopathology. Age-matched HLA-DR3.IFN-c
+/+ (D, E and F) and HLA-
DR3.IFN-c
2/2 (G, H and I) transgenic mice were challenged with SEB (50 mg). Mice were killed 48 hrs later, intestinal segments were collected in
buffered formalin and processed for H&E. Panels A, B and C – sections from naı ¨ve HLA-DR3.IFN-c
+/+ mice shown for comparison. The bar corresponds
to 100 mM.
doi:10.1371/journal.pone.0016764.g010
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any sensitizing agents such as D-galactosamine or bacterial
lipopolysaccharide (LPS) [18,37,38,39,40,41]. TSS seen in HLA
class II transgenic mice also closely mimics the human disease
[22,23]. Therefore, we used HLA-DR3 transgenic mice to
evaluate the role of IFN-c in the pathogenesis of TSS.
Antibody mediated neutralization of IFN-c provided significant
protection against lethal TSS indicating a critical role for IFN-c in
the lethality of TSS. Availability of HLA-DR3.IFN-c
2/2 mice
facilitated the understanding of the mechanisms by which IFN-c
contributes to the lethality of TSS. Surprisingly, IFN-c deficiency
did not attenuate the extent of inflammation in lungs and liver.
These observations concurred with the anti-inflammatory prop-
erties of IFN-c [27,28,29]. Similarly, SAg-induced T cell
expansion was more robust in HLA-DR3.IFN-c
2/2 mice. It is
known that T cells from HLA-DR3.IFN-c
2/2 mice proliferate
more robustly to antigen-specific and non-antigen-specific
stimulation in vivo and in vitro [42,43]. Therefore, it was not
surprising to find increased T cell proliferation in HLA-DR3.IFN-
c
2/2 mice. However, the difference in gut pathology between
HLA-DR3.IFN-c
+/+ and HLA-DR3.IFN-c
2/2 mice provided
some clues about possible pathways by which IFN-c deficiency
might have protected from lethality associated with TSS.
The involvement of gut in TSS has not been described earlier.
Similarly, the role of IFN-c in eliciting gut pathology in TSS has not
been described before. However, IFN-c is known to exert
pathogenic effects on the intestinal epithelial cells, especially in the
small intestine [44,45]. For example, a recent study has shown that
IFN-c induces intestinal epithelial cell death. As a result, IFN-c
2/2
mice have conserved intestinal epithelial integrity following an
inflammatory insult and therefore show increased survival [46,47].
Similar observations were made in the current study. Paradoxically,
IFN-c deficiency did not affect inflammation in lungs or liver, but at
the same time it protected small intestines from pathology. To our
Figure 11. Effect of IFN-c deficiency on SEB-induced duodenal immunopathology. Age-matched HLA-DR3.IFN-c
+/+ (A, C and E) and HLA-
DR3.IFN-c
2/2 (B, D and F) transgenic mice were challenged with SEB (50 mg). Mice were killed at 24, 48 and 72 hrs, duodenal segments were collected
in buffered formalin and processed for H&E. The bar corresponds to 100 mM.
doi:10.1371/journal.pone.0016764.g011
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systems has not been reported. It remains to be elucidated whether
IFN-c acts directly on the intestinal epithelial cells to bring forth the
pathological changes or its effects are mediated indirectly through
other molecular mediators. Unfortunately, the non-availability of
KO mice with targeted disruption of IFN-c receptor only on the
intestinal epithelial cells precludes undertaking of any such studies.
Nonetheless, several experiments done with isolated intestinal
epithelial cells suggest a direct role for IFN-c in eliciting intestinal
epithelial cell pathology [48,49]. D-galN sensitized TSS, has been
shown to be a TNF-a mediated hepatotoxic process [50]. The
susceptibility of HLA-DR3.IFN-c
2/2 mice to D-galN sensitized
TSS further underscored the significance of IFN-c in eliciting the
small intestinal pathology. Taken together, our study suggests that
IFN-c-dependent small intestinal pathology and dysfunction, plays
a significant role in the lethality of SAg-induced of TSS. The next
step would be to verify if in vivo neutralization of IFN-c is a viable
therapeutic option in human TSS. Future studies using our mouse
model would pave a strong foundation for such clinical studies
regarding in vivo neutralization/antagonization of IFN-c.
Supporting Information
Figure S1 IFN-c KO mice are protected from TSS induced by
twice the lethal amount of SEB. Age-matched WT (HLA-
DR3.IFN-c
+/+) and KO (HLA-DR3.IFN-c
2/2) DR3 mice were
challenged with 100 mg of SEB. Body temperature, activity and
mortality were determined as in Fig. 1.
(TIF)
Figure S2 Splenocytes from IFN-c KO mice proliferate more
vigorouslyto SEB stimulation in vitro. Splenocytes from age-matched
WT (HLA-DR3.IFN-c
+/+)a n dK O( H L A - D R 3 . I F N - c
2/2)D R 3
mice were cultured in vitro with SEB and cell proliferation was
determined by thymidine incorporation assay. Representative data
shown.
(TIF)
Figure S3 No defect in T cell activation in IFN-c KO mice in
response to SEB. Age-matched WT (HLA-DR3.IFN-c
+/+) and
KO (HLA-DR3.IFN-c
2/2) DR3 mice were challenged with SEB.
Splenocytes were analyzed by flowcytometry for expression profile
of activation markers. Expression profile of CD69 shown.
(TIF)
Figure S4 Minimal intestinal immunopathology in KO DR3
mice. Age-matched WT (HLA-DR3.IFN-c
+/+) and KO (HLA-
DR3.IFN-c
2/2) DR3 mice were challenged with a lethal dose of
SEB. Intestinal segments were collected at indicated time points
and evaluated by H&E staining.
(TIF)
Figure S5 Minimal intestinal immunopathology in KO DR3
mice. Age-matched WT (HLA-DR3.IFN-c
+/+) and KO (HLA-
DR3.IFN-c
2/2) DR3 mice were challenged with a lethal dose of
SEB. Figure shows representative images acquired at higher
magnification from jejunal sections at 72 hrs.
(TIF)
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